Anti–IL-5Rα monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity to deplete eosinophils and basophils.
Afucosylated humanized monoclonal antibody targeting IL-5 receptor alpha (IL-5Rα). Binds IL-5Rα on eosinophils and basophils and triggers enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), leading to depletion/apoptosis of these cells and suppression of eosinophilic inflammation.
YES
DIRECT
Benralizumab binds IL-5Rα on eosinophils/basophils and engages FcγRIIIa on NK cells (enhanced by afucosylation), triggering antibody-dependent cell-mediated cytotoxicity and apoptosis, depleting the target-expressing cells.
CD20×CD3 bispecific IgG that engages T cells via CD3 to redirect cytotoxicity against CD20-positive B cells.
Bispecific IgG that binds CD20 on B cells and CD3 on T cells, crosslinking them to form an immunologic synapse and redirect T‑cell cytotoxicity to lyse CD20‑positive malignant B cells.
YES
DIRECT
Glofitamab bridges CD20 on target B cells and CD3 on T cells, forming an immunologic synapse that activates T cells to kill CD20+ cells via perforin/granzyme-mediated cytotoxicity.
CD20×CD3 bispecific IgG that engages T cells via CD3 to redirect cytotoxicity against CD20-positive B cells.
Bispecific IgG that binds CD20 on B cells and CD3 on T cells, crosslinking them to form an immunologic synapse and redirect T‑cell cytotoxicity to lyse CD20‑positive malignant B cells.
NO
INDIRECT
Glofitamab uses CD3ε on T cells to engage and activate them while binding CD20 on B cells; activated T cells kill CD20+ B cells via perforin/granzyme cytotoxicity. CD3ε-expressing T cells are not the killed cells.
Chimeric anti-CD20 monoclonal IgG1 antibody that depletes B cells via ADCC, complement activation, and apoptosis.
Chimeric anti-CD20 IgG1 monoclonal antibody that binds CD20 on B cells and depletes CD20-positive malignant and normal B cells via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and induction of apoptosis.
YES
DIRECT
Anti-CD20 antibody binds CD20 on B cells and induces killing via ADCC (FcγR+ NK/macrophages), complement-dependent cytotoxicity (MAC), and direct apoptotic signaling.
Bispecific T-cell–engager antibody immunotherapy that bridges CD19+ B cells and T cells, binding CD19 on B cells and engaging T cells to activate a cytotoxic response against CD19-expressing cells; administered IV once weekly; evaluated as monotherapy in relapsed/refractory CD19+ B-ALL.
Bispecific antibody that links CD19+ B-lineage leukemia cells to T cells—binding CD19 on tumor cells and engaging T cells (via CD3) to trigger T-cell activation and cytotoxic killing of CD19-expressing cells.
NO
INDIRECT
The bispecific binds CD3ε on T cells to activate and redirect them; the activated T cells kill CD19+ tumor cells (perforin/granzyme). CD3ε-expressing T cells are not killed by the drug.